Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy

Hypertension

Volumn 63, Issue 4, 2014, Pages 713-722

  Jiang, Ding Sheng ^a,b   Liu, Yu ^a,b   Zhou, Heng ^a,b   Zhang, Yan ^a,b   Zhang, Xiao Dong ^b   Zhang, Xiao Fei ^b   Chen, Ke ^b   Gao, Lu ^c   Peng, Juan ^d   Gong, Hui ^d   Chen, Yingjie ^e   Yang, Qinglin ^f   Liu, Peter P ^g   Fan, Guo Chang ^h   Zou, Yunzeng ^d   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c Union Hospital   (China)

^d FUDAN UNIVERSITY   (China)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

cardiomegaly; fibrosis; interferon regulatory factor 7

Indexed keywords

ANGIOTENSIN II; GREEN FLUORESCENT PROTEIN; I KAPPA B KINASE BETA; INTERFERON REGULATORY FACTOR 7; MYOSIN HEAVY CHAIN BETA; PHENYLEPHRINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FIBROSIS; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IN VITRO STUDY; INTRACELLULAR SIGNALING; LUNG WEIGHT; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION;

CARDIOMEGALY; FIBROSIS; INTERFERON REGULATORY FACTOR 7;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HYPERTROPHY; I-KAPPA B KINASE; INTERFERON REGULATORY FACTOR-7; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84897045727     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02653     Document Type: Article

References (49)

1. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, Bai X, Zhou H, Jiang H, Heximer SP, Qin M, Huang H, Liu PP, Huang C. Regulator of G protein signaling 5 protects against cardiac hypertrophy and fbrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci USA. 2010;107:13818-13823.
2. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575.
3. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
4. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500-508.
5. Li H, Tang QZ, Liu C, Moon M, Chen M, Yan L, Bian ZY, Zhang Y, Wang AB, Nghiem MP, Liu PP. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension. 2010;56:1109-1117.
6. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med. 2005;38:243-257.
7. Huang H, Tang QZ, Wang AB, Chen M, Yan L, Liu C, Jiang H, Yang Q, Bian ZY, Bai X, Zhu LH, Wang L, Li H. Tumor suppressor A20 protects against cardiac hypertrophy and fbrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension. 2010;56:232-239.
8. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC, Li H. Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension. 2013;61:1193-1202.
9. Yan L, Wei X, Tang QZ, Feng J, Zhang Y, Liu C, Bian ZY, Zhang LF, Chen M, Bai X, Wang AB, Fassett J, Chen Y, He YW, Yang Q, Liu PP, Li H. Cardiac-specifc mindin overexpression attenuates cardiac hypertrophy via blocking akt/gsk3beta and tgf-beta1-smad signalling. Cardiovasc Res. 2011;92:85-94.
10. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracel-lular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
11. Kim Y, Phan D, van Rooij E, Wang DZ, McAnally J, Qi X, Richardson JA, Hill JA, Bassel-Duby R, Olson EN. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest. 2008;118:124-132.
12. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6:644-658.
13. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535-584.
14. Battistini A. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J Interferon Cytokine Res. 2009;29:765-780.
15. Lu J, Bian Z Y, Zhang R, et al. Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol. 2013;108:326.
16. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modifcation and function. Genes Immun. 2011;12:399-414.
17. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772-777.
18. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem. 2004;279:45194-45207.
19. Ning S, Huye LE, Pagano JS. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J Biol Chem. 2005;280:12262-12270.
20. Paz S, Hiscott J. CuRTAiling interferon regulatory factor signaling with the E3 ligase RAUL. Immunity. 2010;33:833-835.
21. Zhang L, Zhang J, Lambert Q, Der CJ, Del Valle L, Miklossy J, Khalili K, Zhou Y, Pagano JS. Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol. 2004;78:12987-12995.
22. Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber DA, Harkin DP. BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem. 2002;277:26225-26232.
23. Xiao J, Moon M, Yan L, Nian M, Zhang Y, Liu C, Lu J, Guan H, Chen M, Jiang D, Jiang H, Liu PP, Li H. Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction. Basic Res Cardiol. 2012;107:239.
24. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110-118.
25. Neuman RE, Logan MA. The determination of hydroxyproline. J Biol Chem. 1950;184:299-306.
26. Stewart MJ, Smoak K, Blum MA, Sherry B. Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specifc in the cardiac protective response. J Virol. 2005;79:2979-2987.
27. Pandya K, Kim HS, Smithies O. Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA. 2006;103:16864-16869.
28. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663.
29. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of nf-kappab in the heart: To be or not to nf-kappab. Circ Res. 2011;108:1122-1132.
30. Zhang L, Pagano JS. Structure and function of IRF-7. J Interferon Cytokine Res. 2002;22:95-101.
31. Servant MJ, Tenoever B, Lin R. Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J Interferon Cytokine Res. 2002;22:49-58.
32. Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J Biol Chem. 2007;282:15325-15329.
33. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 1997;88:213-222.
34. Kwak YT, Guo J, Shen J, Gaynor RB. Analysis of domains in the IKKalpha and IKKbeta proteins that regulate their kinase activity. J Biol Chem. 2000;275:14752-14759.
35. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, Ohba Y, Takaoka A, Yeh WC, Taniguchi T. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA. 2004;101:15416-15421.
36. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol. 2004;5:1061-1068.
37. Maier HJ, Schips TG, Wietelmann A, Kruger M, Brunner C, Sauter M, Klingel K, Bottger T, Braun T, Wirth T. Cardiomyocyte-specifc ikappab kinase (ikk)/nf-kappab activation induces reversible infammatory cardiomy-opathy and heart failure. Proc Natl Acad Sci USA. 2012;109:11794-11799.
38. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA. 2001;98:6668-6673.
39. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011;89:129-138.
40. Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res. 2012;110:1077-1086.
41. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005;111:2319-2325.
42. Hikoso S, Yamaguchi O, Nakano Y, et al. The I{kappa}B kinase {beta}/nuclear factor {kappa}B signaling pathway protects the heart from hemo-dynamic stress mediated by the regulation of manganese superoxide dis-mutase expression. Circ Res. 2009;105:70-79.
43. Kratsios P, Huth M, Temmerman L, Salimova E, Al Banchaabouchi M, Sgoifo A, Manghi M, Suzuki K, Rosenthal N, Mourkioti F. Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKKgamma in cardiomyocytes. Circ Res. 2010;106:133-144.
44. Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother. 2010;59:489-510.
45. Zhang R, Chen K, Peng L, Xiong H. Regulation of T helper cell differentiation by interferon regulatory factor family members. Immunol Res. 2012;54:169-176.
46. Wang XA, Zhang R, She ZG, Zhang XF, Jiang DS, Wang T, Gao L, Deng W, Zhang SM, Zhu LH, Guo S, Chen K, Zhang XD, Liu DP, Li H. Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology. 2013. In Press.
47. Wang XA, Zhang R, Jiang D, et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology. 2013;58:603-616.
48. Wang XA, Zhang R, Zhang S, Deng S, Jiang D, Zhong J, Yang L, Wang T, Hong S, Guo S, She ZG, Zhang XD, Li H. Interferon regulatory factor 7 defciency prevents diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2013;305:E485-E495.
49. Jiang DS, Luo YX, Zhang R, Zhang XD, Chen HZ, Zhang Y, Chen K, Zhang SM, Fan GC, Liu PP, Liu DP, Li H. Interferon Regulatory Factor 9 Protects Against Cardiac Hypertrophy by Targeting Myocardin. Hypertension. 2014;63:119-127.